Appendix 4C - Quarterly Cashflow report
Starpharma today released its Appendix 4C - Quarterly Cashflow report for the period ended 30 September 2012
Starpharma's new formulations demonstrate further improvement in crop protection
Starpharma today announced that its new agrochemical dendrimer formulations have shown further improved features compared to commercially available products.
The Australian: Criterion - Curing Cancer
Respected Criterion columnist for The Australian Tim Boreham reported on promising results from Starpharma’s latest studies to improve leading cancer drug docetaxel, with its proprietary dendrimer technology. He also commented on Starpharma’s very promising VivaGel portfolio.
Starpharma's docetaxel demonstrates targeted tumour delivery
Starpharma today reported significant tumour-targeting results with its proprietary dendrimer-docetaxel formulation.
VivaGel BV Phase 3 trials - recruitment complete
Starpharma today announced completion of recruitment in its two Phase 3 trials investigating VivaGel® as a treatment for bacterial vaginosis (BV).